New and novel approaches for enhancing the oral absorption and bioavailability of protein and peptides therapeutics

References

• 1. Bruno BJ, Miller GD, Lim CS. Basics and recent advances in peptide and protein drug delivery. Ther. Deliv. 4(11), 1443–1467 (2013).
  CASGoogle Scholar
• 2. Tsomaia N. Peptide therapeutics: targeting the undruggable space. Eur. J. Med. Chem. 94, 459–470 (2015).
  Medline CASGoogle Scholar
• 3. Ismail R, Csoka I. Novel strategies in the oral delivery of antidiabetic peptide drugs–Insulin, GLP 1 and its analogs. Eur J Pharm Biopharm. 115, 257–267 (2017).
  Medline CASGoogle Scholar
• 4. Fosgerau K, Hoffmann T. Peptide therapeutics: current status and future directions. Drug Discov. Today 20(1), 122–128 (2015).
  Medline CASGoogle Scholar
• 5. Market Research Engine. Peptide Therapeutic Market Research Report. www.marketresearchengine.com/peptide-therapeutic-market
  Google Scholar
• 6. Grand view research. Peptide Therapeutic Market Size Worth.. www.grandviewwresearch.com/industry-analysis/peptides-therapeutics-market
  Google Scholar
• 7. Brown TD, Whitehead KA, Mitragotri S. Materials for oral delivery of proteins and peptides. Nat. Rev. Materials 5, 1–22 (2019).
  Google Scholar
• 8. Lewis AL, Richard J. Challenges in the delivery of peptide drugs: an industry perspective. Ther. Deliv. 6(2), 149–163 (2015).
  CASGoogle Scholar
• 9. Usmani SS, Bedi G, Samuel JS et al. THPdb: database of FDA-approved peptide and protein therapeutics. PLoS ONE 12(7), e0181748 (2017).
  MedlineGoogle Scholar
• 10. Leader B, Baca QJ, Golan DE. Protein therapeutics: a summary and pharmacological classification. Nat. Rev. Drug Discov. 7(1), 21–39 (2008).
  Medline CASGoogle Scholar
• 11. Mullard A. 2017 FDA drug approvals. (2018). www.nature.com/articles/nrd.2018.4
  Google Scholar
• 12. Wright L, Barnes T, Prestidge C. Oral delivery of protein-based therapeutics: gastroprotective strategies, physiological barriers and in vitro permeability prediction. Int. J. Pharm. 585, 119488 (2020).
  Medline CASGoogle Scholar
• 13. Yin N, Brimble MA, Harris PW, Wen J. Enhancing the oral bioavailability of peptide drugs by using chemical modification and other approaches. Med. Chem 4(12), 763–769 (2014).
  Google Scholar
• 14. Lundquist P, Artursson P. Oral absorption of peptides and nanoparticles across the human intestine: opportunities, limitations and studies in human tissues. Adv. Drug Deliv. Rev. 106, 256–276 (2016).
  Medline CASGoogle Scholar
• 15. Renukuntla J, Vadlapudi AD, Patel A, Boddu SH, Mitra AK. Approaches for enhancing oral bioavailability of peptides and proteins. Int. J. Pharm. 447(1-2), 75–93 (2013).
  Medline CASGoogle Scholar
• 16. Räder AF, Reichart F, Weinmüller M, Kessler H. Improving oral bioavailability of cyclic peptides by N-methylation. Bioorg. Med. Chem. 26(10), 2766–2773 (2018).
  MedlineGoogle Scholar
• 17. Liu C, Kou Y, Zhang X, Cheng H, Chen X, Mao S. Strategies and industrial perspectives to improve oral absorption of biological macromolecules. Expert Opin. Drug Deliv. 15(3), 223–233 (2018).
  Medline CASGoogle Scholar
• 18. Homayun B, Lin X, Choi H-J. Challenges and recent progress in oral drug delivery systems for biopharmaceuticals. Pharmaceutics 11(3), 129 (2019).
  CASGoogle Scholar
• 19. Drucker DJ. Advances in oral peptide therapeutics. Nat. Rev. Drug Discov. 19, 1–13 (2019).
  Google Scholar
• 20. Anselmo AC, Gokarn Y, Mitragotri S. Non-invasive delivery strategies for biologics. Nat. Rev. Drug Discov. 18, 19–40 (2018).
  MedlineGoogle Scholar
• 21. Kaksonen M, Roux A. Mechanisms of clathrin-mediated endocytosis. Nat. Rev. Mol. Cell Biol. 19(5), 313 (2018).
  Medline CASGoogle Scholar
• 22. Yamamoto A, Ukai H, Morishita M, Katsumi H. Approaches to improve intestinal and transmucosal absorption of peptide and protein drugs. Pharmacol. Ther. 211, 107537 (2020).
  Medline CASGoogle Scholar
• 23. Aungst BJ. Absorption enhancers: applications and advances. AAPS J. 14(1), 10–18 (2012).
  Medline CASGoogle Scholar
• 24. Kalra S, Sahay R. A review on semaglutide: an oral glucagon-like peptide 1 receptor agonist in management of Type 2 diabetes mellitus. Diabetes Ther. 11, 1–18 (2020).
  Google Scholar
• 25. Victor SP, Paul W, Sharma CP. Eligen^® technology for oral delivery of proteins and peptides. In: Mucosal Delivery of Biopharmaceuticals. Springer, 407–422 (2014). https://link.springer.com/chapter/10.1007/978-1-4614-9524-6_18
  Google Scholar
• 26. Fattah S, Ismaiel M, Murphy B et al. Salcaprozate sodium (SNAC) enhances permeability of octreotide across isolated rat and human intestinal epithelial mucosae in Ussing chambers. Eur. J. Pharm. Sci. 154, 105509 (2020).
  Medline CASGoogle Scholar
• 27. Maher S, Brayden DJ. Overcoming poor permeability: translating permeation enhancers for oral peptide delivery. Drug Discov. Today 9(2), e113–e119 (2012).
  CASGoogle Scholar
• 28. Shaji J, Patole V. Protein and peptide drug delivery: oral approaches. Indian J. Pharm. Sci. 70(3), 269 (2008).
  MedlineGoogle Scholar
• 29. Doostmohammadi M, Ameri A, Mohammadinejad R et al. Hydrogels for peptide hormones delivery: therapeutic and tissue engineering applications. Drug Design Devel. Ther. 13, 3405 (2019).
  Medline CASGoogle Scholar
• 30. Agrahari V, Agrahari V, Mitra AK. Nanocarrier fabrication and macromolecule drug delivery: challenges and opportunities. Ther. Deliv. 7(4), 257–278 (2016).
  CASGoogle Scholar
• 31. Moroz E, Matoori S, Leroux J-C. Oral delivery of macromolecular drugs: where we are after almost 100 years of attempts. Adv. Drug Deliv. Rev. 101, 108–121 (2016).
  Medline CASGoogle Scholar
• 32. Ichikawa H, Peppas NA. Novel complexation hydrogels for oral peptide delivery: in vitro evaluation of their cytocompatibility and insulin‐transport enhancing effects using Caco‐2 cell monolayers. J. Biomed. Mater. Res. A 67(2), 609–617 (2003).
  MedlineGoogle Scholar
• 33. Rekha M, Sharma CP. Oral delivery of therapeutic protein/peptide for diabetes–future perspectives. Int. J. Pharm. 440(1), 48–62 (2013).
  Medline CASGoogle Scholar
• 34. Lee HJ, Amidon GL. The effect of enzyme inhibitor and absorption site following [D‐ala2, D‐leu5] enkephalin oral administration in rats. Biopharm. Drug Dispos. 23(4), 131–141 (2002).
  Medline CASGoogle Scholar
• 35. Sosnik A, Das Neves J, Sarmento B. Mucoadhesive polymers in the design of nano-drug delivery systems for administration by non-parenteral routes: a review. Prog. Polym. Sci. 39(12), 2030–2075 (2014).
  CASGoogle Scholar
• 36. Russo E, Selmin F, Baldassari S et al. A focus on mucoadhesive polymers and their application in buccal dosage forms. J. Drug Deliv. Sci. Technol. 32, 113–125 (2016).
  CASGoogle Scholar
• 37. Leitner VM, Walker GF, Bernkop-Schnürch A. Thiolated polymers: evidence for the formation of disulphide bonds with mucus glycoproteins. Eur. J. Pharm. Biopharm. 56(2), 207–214 (2003).
  Medline CASGoogle Scholar
• 38. Millotti G, Laffleur F, Perera G et al. In vivo evaluation of thiolated chitosan tablets for oral insulin delivery. J. Pharm. Sci. 103(10), 3165–3170 (2014).
  Medline CASGoogle Scholar
• 39. Duggan S, Cummins W, O'donovan O, Hughes H, Owens E. Thiolated polymers as mucoadhesive drug delivery systems. Eur. J. Pharm. Sci. 100, 64–78 (2017).
  Medline CASGoogle Scholar
• 40. Muheem A, Shakeel F, Jahangir MA et al. A review on the strategies for oral delivery of proteins and peptides and their clinical perspectives. Saudi Pharm. J. 24(4), 413–428 (2016).
  MedlineGoogle Scholar
• 41. Cao S-J, Xu S, Wang H-M et al. Nanoparticles: oral delivery for protein and peptide drugs. AAPS PharmSciTech 20(5), 190 (2019).
  MedlineGoogle Scholar
• 42. Ibrahim YHY, Regdon G, Hamedelniel EI, Sovány T. Review of recently used techniques and materials to improve the efficiency of orally administered proteins/peptides. DARU J. Pharm. Sci. 28, 1–14 (2020).
  MedlineGoogle Scholar
• 43. Niu Z, Conejos-Sánchez I, Griffin BT, O'driscoll CM, Alonso MJ. Lipid-based nanocarriers for oral peptide delivery. Adv. Drug Deliv. Rev. 106, 337–354 (2016).
  Medline CASGoogle Scholar
• 44. Gupta S, Jain A, Chakraborty M, Sahni JK, Ali J, Dang S. Oral delivery of therapeutic proteins and peptides: a review on recent developments. Drug Deliv. 20(6), 237–246 (2013).
  Medline CASGoogle Scholar
• 45. Niu M, Lu Y, Hovgaard L et al. Hypoglycemic activity and oral bioavailability of insulin-loaded liposomes containing bile salts in rats: the effect of cholate type, particle size and administered dose. Eur. J. Pharm. Biopharm. 81(2), 265–272 (2012).
  Medline CASGoogle Scholar
• 46. Niu M, Lu Y, Hovgaard L, Wu W. Liposomes containing glycocholate as potential oral insulin delivery systems: preparation, in vitro characterization and improved protection against enzymatic degradation. Int. J. Nanomed. 6, 1155 (2011).
  Medline CASGoogle Scholar
• 47. Niu M, Tan YN, Guan P et al. Enhanced oral absorption of insulin-loaded liposomes containing bile salts: a mechanistic study. Int. J. Pharm. 460(1-2), 119–130 (2014).
  Medline CASGoogle Scholar
• 48. Cui M, Wu W, Hovgaard L, Lu Y, Chen D, Qi J. Liposomes containing cholesterol analogues of botanical origin as drug delivery systems to enhance the oral absorption of insulin. Int. J. Pharm. 489(1-2), 277–284 (2015).
  Medline CASGoogle Scholar
• 49. Gradauer K, Barthelmes J, Vonach C et al. Liposomes coated with thiolated chitosan enhance oral peptide delivery to rats. J. Control. Rel. 172(3), 872–878 (2013).
  Medline CASGoogle Scholar
• 50. Han Y, Gao Z, Chen L et al. Multifunctional oral delivery systems for enhanced bioavailability of therapeutic peptides/proteins. Acta Pharm. Sin. B 9(5), 902–922 (2019).
  MedlineGoogle Scholar
• 51. Lin C-H, Chen C-H, Lin Z-C, Fang J-Y. Recent advances in oral delivery of drugs and bioactive natural products using solid lipid nanoparticles as the carriers. J. Food Drug Anal. 25(2), 219–234 (2017).
  Medline CASGoogle Scholar
• 52. Lakkireddy HR, Urmann M, Besenius M et al. Oral delivery of diabetes peptides – comparing standard formulations incorporating functional excipients and nanotechnologies in the translational context. Adv. Drug Deliv. Rev. 106, 196–222 (2016).
  Medline CASGoogle Scholar
• 53. Batista P, Castro PM, Madureira AR, Sarmento B, Pintado M. Recent insights in the use of nanocarriers for the oral delivery of bioactive proteins and peptides. Peptides 101, 112–123 (2018).
  Medline CASGoogle Scholar
• 54. Dumont C, Bourgeois S, Fessi H, Jannin V. Lipid-based nanosuspensions for oral delivery of peptides, a critical review. Int. J. Pharm. 541(1-2), 117–135 (2018).
  Medline CASGoogle Scholar
• 55. Dumont C, Bourgeois S, Fessi H, Dugas P-Y, Jannin V. In-vitro evaluation of solid lipid nanoparticles: ability to encapsulate, release and ensure effective protection of peptides in the gastrointestinal tract. Int. J. Pharm. 565, 409–418 (2019).
  Medline CASGoogle Scholar
• 56. Krstić M, Medarević Đ, Đuriš J, Ibrić S. Self-nanoemulsifying drug delivery systems (SNEDDS) and self-microemulsifying drug delivery systems (SMEDDS) as lipid nanocarriers for improving dissolution rate and bioavailability of poorly soluble drugs. In: Lipid Nanocarriers for Drug Targeting. Elsevier, 473–508 (2018). www.sciencedirect.com/science/article/pii/B9780128136874000128
  Google Scholar
• 57. Mahmood A, Bernkop-Schnürch A. SEDDS: a game changing approach for the oral administration of hydrophilic macromolecular drugs. Adv. Drug Deliv. Rev. 142, 91–101 (2019).
  Medline CASGoogle Scholar
• 58. Karamanidou T, Karidi K, Bourganis V, Kontonikola K, Kammona O, Kiparissides C. Effective incorporation of insulin in mucus permeating self-nanoemulsifying drug delivery systems. Eur. J. Pharm. Biopharm. 97, 223–229 (2015).
  Medline CASGoogle Scholar
• 59. Li P, Tan A, Prestidge CA, Nielsen HM, Müllertz A. Self-nanoemulsifying drug delivery systems for oral insulin delivery: in vitro and in vivo evaluations of enteric coating and drug loading. Int. J. Pharm. 477(1-2), 390–398 (2014).
  Medline CASGoogle Scholar
• 60. Garg V, Kaur P, Singh SK et al. Solid self-nanoemulsifying drug delivery systems for oral delivery of polypeptide-k: formulation, optimization, in-vitro and in-vivo antidiabetic evaluation. Eur. J. Pharm. Sci. 109, 297–315 (2017).
  Medline CASGoogle Scholar
• 61. Dogru S, Calis S, Öner F. Oral multiple w/o/w emulsion formulation of a peptide salmon calcitonin: in vitro‐in vivo evaluation. J. Clin. Pharm. Ther. 25(6), 435–443 (2000).
  Medline CASGoogle Scholar
• 62. Venkata Siddhartha T, Senthil V, Sai Kishan I, Basha Khatwal R, V Madhunapantula S. Design and development of oral nanoparticulated insulin in multiple emulsion. Current drug delivery 11(4), 472–485 (2014).
  MedlineGoogle Scholar
• 63. Garcıa-Fuentes M, Torres D, Alonso M. Design of lipid nanoparticles for the oral delivery of hydrophilic macromolecules. Colloids Surf. B 27(2-3), 159–168 (2003).
  CASGoogle Scholar
• 64. Li X, Qi J, Xie Y et al. Nanoemulsions coated with alginate/chitosan as oral insulin delivery systems: preparation, characterization and hypoglycemic effect in rats. Int. J. Nanomed. 8, 23 (2013).
  Medline CASGoogle Scholar
• 65. Agrawal GR, Wakte P, Shelke S. Formulation, physicochemical characterization and in vitro evaluation of human insulin-loaded microspheres as potential oral carrier. Prog. Biomaterials 6(3), 125–136 (2017).
  Medline CASGoogle Scholar
• 66. Barclay TG, Day CM, Petrovsky N, Garg S. Review of polysaccharide particle-based functional drug delivery. Carbohydr. Polym. 221, 94–112 (2019).
  Medline CASGoogle Scholar
• 67. Lang X, Wang T, Sun M, Chen X, Liu Y. Advances and applications of chitosan-based nanomaterials as oral delivery carriers: a review. Int. J. Biol. Macromol. 154, 433–445 (2020).
  Medline CASGoogle Scholar
• 68. Sonaje K, Lin Y-H, Juang J-H, Wey S-P, Chen C-T, Sung H-W. In vivo evaluation of safety and efficacy of self-assembled nanoparticles for oral insulin delivery. Biomaterials 30(12), 2329–2339 (2009).
  Medline CASGoogle Scholar
• 69. Liu Z, Jiao Y, Wang Y, Zhou C, Zhang Z. Polysaccharides-based nanoparticles as drug delivery systems. Adv. Drug Deliv. Rev. 60(15), 1650–1662 (2008).
  Medline CASGoogle Scholar
• 70. Ji N, Hong Y, Gu Z, Cheng L, Li Z, Li C. Chitosan coating of zein-carboxymethylated short-chain amylose nanocomposites improves oral bioavailability of insulin in vitro and in vivo. J. Control. Rel. 313, 1–13 (2019).
  Medline CASGoogle Scholar
• 71. Wong CY, Al-Salami H, Dass CR. Formulation and characterisation of insulin-loaded chitosan nanoparticles capable of inducing glucose uptake in skeletal muscle cells in vitro. J. Drug Deliv. Sci. Technol. 57, 101738 (2020).
  CASGoogle Scholar
• 72. Maria S, Sarwar HS, Sohail MF et al. Synthesis and characterization of pre-activated thiolated chitosan nanoparticles for oral delivery of octreotide. J. Drug Deliv. Sci. Technol. 58, 101807 (2020).
  CASGoogle Scholar
• 73. Beloqui A, Des Rieux A, Préat V. Mechanisms of transport of polymeric and lipidic nanoparticles across the intestinal barrier. Adv. Drug Deliv. Rev. 106, 242–255 (2016).
  Medline CASGoogle Scholar
• 74. Chin J, Mahmud KF, Kim SE, Park K, Byun Y. Insight of current technologies for oral delivery of proteins and peptides. Drug Discov. Today 9(2), e105–e112 (2012).
  CASGoogle Scholar
• 75. Soudry-Kochavi L, Naraykin N, Nassar T, Benita S. Improved oral absorption of exenatide using an original nanoencapsulation and microencapsulation approach. J. Control. Rel. 217, 202–210 (2015).
  Medline CASGoogle Scholar
• 76. Layek B, Mandal S. Natural polysaccharides for controlled delivery of oral therapeutics: a recent update. Carbohydr. Polym. 230, 115617 (2020).
  Medline CASGoogle Scholar
• 77. Lee S, Kim Y-C, Park J-H. Zein-alginate based oral drug delivery systems: protection and release of therapeutic proteins. Int. J. Pharm. 515(1-2), 300–306 (2016).
  Medline CASGoogle Scholar
• 78. Song Y, Gan W, Li Q, Guo Y, Zhou J, Zhang L. Alkaline hydrolysis and flocculation properties of acrylamide-modified cellulose polyelectrolytes. Carbohydr. Polym. 86(1), 171–176 (2011).
  CASGoogle Scholar
• 79. Maroni A, Del Curto MD, Salmaso S et al. In vitro and in vivo evaluation of an oral multiple-unit formulation for colonic delivery of insulin. Eur. J. Pharm. Biopharm. 108, 76–82 (2016).
  Medline CASGoogle Scholar
• 80. Wu ZM, Zhou L, Guo XD et al. HP55-coated capsule containing PLGA/RS nanoparticles for oral delivery of insulin. Int. J. Pharm. 425(1-2), 1–8 (2012).
  Medline CASGoogle Scholar
• 81. Amirthalingam E, Rodrigues M, Casal-Dujat L et al. Macrocyclic imidazolium-based amphiphiles for the synthesis of gold nanoparticles and delivery of anionic drugs. J. Colloid Interface Sci. 437, 132–139 (2015).
  Medline CASGoogle Scholar
• 82. Cho H-J, Oh J, Choo M-K, Ha J-I, Park Y, Maeng H-J. Chondroitin sulfate-capped gold nanoparticles for the oral delivery of insulin. Int. J. Biol. Macromol. 63, 15–20 (2014).
  Medline CASGoogle Scholar
• 83. Deng W, Xie Q, Wang H, Ma Z, Wu B, Zhang X. Selenium nanoparticles as versatile carriers for oral delivery of insulin: insight into the synergic antidiabetic effect and mechanism. Nanomedicine 13(6), 1965–1974 (2017).
  Medline CASGoogle Scholar
• 84. Zhang Y, Zhang L, Ban Q, Li J, Li C-H, Guan Y-Q. Preparation and characterization of hydroxyapatite nanoparticles carrying insulin and gallic acid for insulin oral delivery. Nanomedicine 14(2), 353–364 (2018).
  CASGoogle Scholar
• 85. Zhao X, Shan C, Zu Y et al. Preparation, characterization and evaluation in vivo of Ins-SiO2-HP55 (insulin-loaded silica coating HP55) for oral delivery of insulin. Int. J. Pharm. 454(1), 278–284 (2013).
  Medline CASGoogle Scholar
• 86. Wagner AM, Gran MP, Peppas NA. Designing the new generation of intelligent biocompatible carriers for protein and peptide delivery. Acta Pharm. Sin. B 8(2), 147–164 (2018).
  MedlineGoogle Scholar
• 87. O'hagan D, Mcgee J, Holmgren J et al. Biodegradable microparticles for oral immunization. Vaccine 11(2), 149–154 (1993).
  MedlineGoogle Scholar
• 88. Maculotti K, Tira EM, Sonaggere M et al. In vitro evaluation of chondroitin sulphate-chitosan microspheres as carrier for the delivery of proteins. J. Microencapsul. 26(6), 535–543 (2009).
  Medline CASGoogle Scholar
• 89. Fonte P, Araújo F, Silva C et al. Polymer-based nanoparticles for oral insulin delivery: revisited approaches. Biotechnol. Adv. 33(6), 1342–1354 (2015).
  Medline CASGoogle Scholar
• 90. Inchaurraga L, Martín-Arbella N, Zabaleta V, Quincoces G, Peñuelas I, Irache JM. In vivo study of the mucus-permeating properties of PEG-coated nanoparticles following oral administration. Eur. J. Pharm. Biopharm. 97, 280–289 (2015).
  Medline CASGoogle Scholar
• 91. Wang H, Zhao Y, Wang H et al. Low-molecular-weight protamine-modified PLGA nanoparticles for overcoming drug-resistant breast cancer. J. Control. Rel. 192, 47–56 (2014).
  Medline CASGoogle Scholar
• 92. Mahajan A, Rawat AS, Bhatt N, Chauhan MK. Structural modification of proteins and peptides. Indian J. Pharm. Educ. Res. 48(3), 34–47 (2014).
  Google Scholar
• 93. Pawar VK, Meher JG, Singh Y, Chaurasia M, Reddy BS, Chourasia MK. Targeting of gastrointestinal tract for amended delivery of protein/peptide therapeutics: strategies and industrial perspectives. J. Control. Rel. 196, 168–183 (2014).
  Medline CASGoogle Scholar
• 94. Chuang E-Y, Lin K-J, Lin P-Y et al. Self-assembling bubble carriers for oral protein delivery. Biomaterials 64, 115–124 (2015).
  Medline CASGoogle Scholar
• 95. Tyagi P, Pechenov S, Subramony JA. Oral peptide delivery: translational challenges due to physiological effects. J. Control. Rel. 287, 167–176 (2018).
  Medline CASGoogle Scholar
• 96. Shenoy B, Wang Y, Shan W, Margolin AL. Stability of crystalline proteins. Biotechnol. Bioeng. 73(5), 358–369 (2001).
  Medline CASGoogle Scholar
• 97. Shahiwala A. Cyclodextrin conjugates for colon drug delivery. J. Drug Deliv. Sci. Technol. 55, 101448 (2020).
  CASGoogle Scholar
• 98. Corazza FG, Ernesto JV, Nambu FA et al. Papain-cyclodextrin complexes as an intestinal permeation enhancer: permeability and in vitro safety evaluation. J. Drug Deliv. Sci. Technol. 55, 101413 (2020).
  CASGoogle Scholar
• 99. Yang L, Li M, Sun Y, Zhang L. A cell-penetrating peptide conjugated carboxymethyl-β-cyclodextrin to improve intestinal absorption of insulin. Int. J. Biol. Macromol. 111, 685–695 (2018).
  Medline CASGoogle Scholar
• 100. Niu Z, Thielen I, Barnett A, Loveday SM, Singh H. ε-Polylysine and β-cyclodextrin assembling as delivery systems for gastric protection of proteins and possibility to enhance intestinal permeation. J. Colloid Interface Sci. 546, 312–323 (2019).
  Medline CASGoogle Scholar
• 101. Maher S, Ryan B, Duffy A, Brayden DJ. Formulation strategies to improve oral peptide delivery. Pharm. Pat. Anal. 3(3), 313–336 (2014).
  CASGoogle Scholar
• 102. Feng K, Li C, Wei Y-S, Zong M-H, Wu H, Han S-Y. Development of a polysaccharide based multi-unit nanofiber mat for colon-targeted sustained release of salmon calcitonin. J. Colloid Interface Sci. 552, 186–195 (2019).
  Medline CASGoogle Scholar
• 103. Xu Y, De Keersmaecker H, Braeckmans K et al. Targeted nanoparticles towards increased L cell stimulation as a strategy to improve oral peptide delivery in incretin-based diabetes treatment. Biomaterials. 255, 120209 (2020).
  Medline CASGoogle Scholar
• 104. Xu Y, Shrestha N, Préat V, Beloqui A. Overcoming the intestinal barrier: a look into targeting approaches for improved oral drug delivery systems. J. Control. Rel. 322, 486–508 (2020).
  Medline CASGoogle Scholar
• 105. Russell-Jones G. Intestinal receptor targeting for peptide delivery: an expert's personal perspective on reasons for failure and new opportunities. Ther. Deliv. 2(12), 1575–1593 (2011).
  Google Scholar
• 106. Qin J-J, Wang W, Sarkar S, Zhang R. Oral delivery of anti-MDM2 inhibitor SP141-loaded FcRn-targeted nanoparticles to treat breast cancer and metastasis. J. Control. Rel. 237, 101–114 (2016).
  Medline CASGoogle Scholar
• 107. Kang SK, Woo JH, Kim MK et al. Identification of a peptide sequence that improves transport of macromolecules across the intestinal mucosal barrier targeting goblet cells. J. Biotechnol. 135(2), 210–216 (2008).
  Medline CASGoogle Scholar
• 108. Wu Y, Tang L, Wang B, Sun Q, Zhao P, Li W. The role of autophagy in maintaining intestinal mucosal barrier. J. Cell. Physiol. 234(11), 19406–19419 (2019).
  Medline CASGoogle Scholar
• 109. Jin Y, Song Y, Zhu X et al. Goblet cell-targeting nanoparticles for oral insulin delivery and the influence of mucus on insulin transport. Biomaterials 33(5), 1573–1582 (2012).
  Medline CASGoogle Scholar
• 110. Azizi A, Kumar A, Diaz-Mitoma F, Mestecky J. Enhancing oral vaccine potency by targeting intestinal M cells. PLoS Pathog. 6(11), e1001147 (2010).
  MedlineGoogle Scholar
• 111. Beloqui A, Brayden DJ, Artursson P, Préat V, Des Rieux A. A human intestinal M-cell-like model for investigating particle, antigen and microorganism translocation. Nat. Protoc. 12(7), 1387 (2017).
  Medline CASGoogle Scholar
• 112. Ma CZ-H, Zheng Y-P, Lee WC-C. Changes in gait and plantar foot loading upon using vibrotactile wearable biofeedback system in patients with stroke. Top. Stroke Rehabil. 25(1), 20–27 (2018).
  MedlineGoogle Scholar
• 113. Diesner SC, Bergmayr C, Wang X-Y et al. Characterization of Vibrio cholerae neuraminidase as an immunomodulator for novel formulation of oral allergy immunotherapy. Clin. Immunol. 192, 30–39 (2018).
  Medline CASGoogle Scholar
• 114. Engel A, Benedikt A, Baer MH. An innovative smart oral delivery technology for proteins and peptides. ONdrugDelivery Magazine 69, 8–11 (2016).
  Google Scholar
• 115. Enteris Biopharma. Peptelligence. https://enterisbiopharma.com/peptelligence/
  Google Scholar
• 116. Emisphere. The Eligen Technology. https://emisphere.com/technology/
  Google Scholar
• 117. Malkov D, Angelo R, Wang H-Z, Flanders E, Tang H, Gomez-Orellana I. Oral delivery of insulin with the eligen (^®) technology: mechanistic studies. Curr. Drug Deliv. 2(2), 191–197 (2005).
  Medline CASGoogle Scholar
• 118. Aguirre TA, Teijeiro-Osorio D, Rosa M, Coulter I, Alonso M, Brayden D. Current status of selected oral peptide technologies in advanced preclinical development and in clinical trials. Adv. Drug Deliv. Rev. 106, 223–241 (2016).
  Medline CASGoogle Scholar
• 119. Eldor R, Arbit E, Miteva Y, Freier R, Kidron M. Oral insulin: Type I diabetes (T1DM) patient response upon pre-prandial administration. Presented at: 70th American Diabetis Association Scientific sessions. Orlando, 25–30 June 2010.
  Google Scholar
• 120. Kidron M, Dinh S, Menachem Y et al. A novel per‐oral insulin formulation: proof of concept study in non‐diabetic subjects. Diabet. Med. 21(4), 354–357 (2004).
  Medline CASGoogle Scholar
• 121. Oramed Pharmaceuticals. www.oramed.com
  Google Scholar
• 122. Oramed. Kidron.Methods and compositions for oral administration of exenatide. USPTO,10,350,162 (2017). http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=10350162.PN.&OS=PN/10350162&RS=PN/10350162/
  Google Scholar
• 123. Clinical Trials. https://clinicaltrials.gov/ct2/show/NCT00948493
  Google Scholar
• 124. Wajcberg E, Miyazaki Y, Triplitt C, Cersosimo E, Defronzo RA. Dose-response effect of a single administration of oral hexyl-insulin monoconjugate 2 in healthy nondiabetic subjects. Diabetes Care 27(12), 2868–2873 (2004).
  Medline CASGoogle Scholar
• 125. Madhav M. Long-awaited dream of oral insulin: where did we reach. Asian J. Pharm. Clin. Res 4(2), 15–20 (2011).
  Google Scholar
• 126. Khedkar A, Iyer H, Anand A et al. A dose range finding study of novel oral insulin (IN‐105) under fed conditions in type 2 diabetes mellitus subjects. Diabetes, Obesity and Metabolism 12(8), 659–664 (2010).
  Medline CASGoogle Scholar
• 127. Radhakrishnan Diabetes Orlando (25–30 June, 2010).
  Google Scholar
• 128. Whitelaw DC, Kelly CA, Ironmonger W, Cunliffe C, New R, Phillips JN. Absorption of orally ingested insulin in human type 1 diabetic subjects: proof of concept study. Diabetes 54(Suppl. 1), (2005).
  Google Scholar
• 129. Schwartz S, Geho B, Rosenberg L, Lau J. Insulin routes (SC and oral) and SC human insulin in patients with type 1 diabetes mellitus. Presented at: Diabetes 2008.
  Google Scholar
• 130. Lau: Diasome Pharmaceuticals. Orally bioavailable lipid-based constructs. US 8,962,015. (2015). http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=8962015.PN.&OS=PN/8962015&RS=PN/8962015
  Google Scholar
• 131. Vehik K, Cuthbertson D, Ruhlig H et al. Long-term outcome of individuals treated with oral insulin: Diabetes Prevention Trial–Type 1 (DPT-1) oral insulin trial. Diabetes Care 34(7), 1585–1590 (2011).
  MedlineGoogle Scholar
• 132. Van Mourik ID, Thomson M, Kelly DA. Comparison of pharmacokinetics of Neoral and Sandimmune in stable pediatric liver transplant recipients. Liver Transplant. Surg. 5(2), 107–111 (1999).
  Medline CASGoogle Scholar
• 133. Chiasma Pharma. www.chiasmapharma.com
  Google Scholar
• 134. Asi Haviv: CHIASMA INC. Oral octreotide administered in combination with other therapeutic agents. US 20160193285 A1. (2016). https://patents.google.com/patent/US20160193285?oq=chiasma+Haviv
  Google Scholar
• 135. Jensen. Tablet formulation comprising semaglutide and a delivery agent. US 9,993,430. (2018). http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=9993430.PN.&OS=PN/9993430&RS=PN/9993430
  Google Scholar
• 136. Imran M. Rani Therapeutics. www.prnewswire.com/news-releases/rani-therapeutics-announces-positive-phase-i-study-results-of-oral-octreotide-using-ranipill-300992818.html?tc=eml_cleartime
  Google Scholar
• 137. Pharm Film Technology. https://aquestive.com/innovative-drug-delivery-pharmfilm/
  Google Scholar
• 138. Neurelis. Neurelis Drug Delivery Technologies. www.neurelis.com/our-technologies
  Google Scholar
• 139. Credentis.CUROLOX Technology. www.credentis.com/en/innovation-science/
  Google Scholar
• 140. Biolingus. The OPUS Technology. www.biolingus.ch/tech_3.html#:∼:text=OPUS%20Technology,and%20%22pre%2Ddiabetes%22
  Google Scholar